The EU HTA Regulation Is Reshaping How Clinical Evidence Supports Market Access Across Europe
- 2 minutes ago
- 14 min read
On 30 April 2026, a milestone quietly passed that will redefine how innovative medicines reach patients across the European Union. The HTA Coordination Group (HTACG) approved the very first Joint Clinical Assessment (JCA) report in history — covering tovorafenib (Ojemda®), Ipsen's treatment for paediatric low-grade malignant glioma. Completed well within the 30-day timeline from marketing authorisation, it marked the first real-world product of a regulatory and market access transformation that has been in motion since 12 January 2025, when the EU Health Technology Assessment (HTA) Regulation formally came into force.
For pharmaceutical companies, biotech developers, medical device manufacturers, and the regulatory and market access professionals who support them, the implications of this regulation extend far beyond a single product assessment. The EU HTA Regulation — formally Regulation (EU) 2021/2282 — fundamentally changes the relationship between clinical evidence, regulatory approval, and patient access to medicines across all 27 EU member states. Understanding it is no longer optional. It is a strategic necessity.
Ready to Build a Career at the Interface of Regulatory Affairs and Market Access? At Entry to Regulatory, we provide intensive, practical training courses for anyone looking to break into Regulatory Affairs — even with zero prior experience. Our programme covers EU, US, and UK regulations over 50+ CPD hours, pairs you with real-world work assignments, and gives you dedicated CV support, mock interviews, and job placement mentoring. Graduates are landing roles within weeks to months of completing the course. it. Speak to us and see how we can help you.
What Is the EU HTA Regulation — and What Problem Is It Solving?
To understand why the EU HTA Regulation represents such a significant shift, it is worth understanding what existed before it — and why that system was failing patients, industry, and health systems alike.
Before the regulation came into force, a pharmaceutical company seeking to bring a new medicine to patients across the EU faced an extraordinary duplication of effort. After obtaining a centralised marketing authorisation from the EMA — a single, pan-EU regulatory decision — the same company then had to conduct up to 27 separate national HTA processes to support reimbursement applications in each member state. Each national HTA body had its own evidence requirements, its own comparator preferences, its own methodological standards, and its own timelines. A clinical dossier acceptable to Germany's IQWiG might fail to satisfy France's HAS. Evidence sufficient in the Netherlands might be rejected in Sweden.
The result was profound inefficiency: enormous duplication of work for developers, inconsistent patient access across Europe (with wealthier member states often gaining access years before smaller ones), and fragmented clinical knowledge that served no-one well. Patients in some member states waited years for treatments already available to their neighbours — not because of clinical evidence gaps, but because of bureaucratic and methodological fragmentation.
The EU HTA Regulation was designed to address this directly by introducing a single, EU-wide Joint Clinical Assessment of the clinical evidence — conducted once, collaboratively, by multiple member states working together — that can then inform national reimbursement decisions across the union.
The Three Pillars of the EU HTA Regulation
The regulation is built around three core mechanisms, each addressing a distinct point in the development and access journey.
Pillar 1: Joint Clinical Assessments (JCAs)
The JCA is the centrepiece of the regulation. It is a centralised, collaborative scientific evaluation of the clinical evidence for a new medicine — specifically its relative clinical effectiveness compared to existing treatments — conducted by the HTACG with the involvement of national HTA experts from across the EU.
What the JCA covers:
- Clinical effectiveness — does the medicine provide a meaningful benefit to patients compared to relevant alternatives?
- Safety — what are the relative risks compared to comparators?
- Clinical evidence quality — how robust, relevant, and generalisable is the data submitted?
What the JCA does NOT cover:
- Cost-effectiveness — economic evaluation remains entirely national
- Pricing — pricing decisions remain with individual member states
- Reimbursement — reimbursement decisions remain national
This distinction is critical and frequently misunderstood. The JCA produces a clinical evidence report, not a reimbursement decision. Member states remain sovereign in their pricing and access decisions. The JCA provides a shared scientific foundation — reducing the need for 27 separate clinical evidence reviews — but each member state retains full control over whether and how they reimburse a product.
The rollout timeline:
- January 2025: JCAs mandatory for new oncology medicines and Advanced Therapy Medicinal Products (ATMPs) — gene therapies, cell therapies, tissue-engineered products
- 2028: Scope extends to orphan medicines for rare diseases
- 2030: All other new medicinal products included
- High-risk medical devices are also being scoped for inclusion in the JCA framework
Pillar 2: Joint Scientific Consultations (JSCs)
The second pillar — Joint Scientific Consultations — provides developers with the opportunity to engage with HTA bodies at an early stage of clinical development to align their evidence generation strategy with what the JCA process will require.
JSCs are, in effect, the HTA equivalent of the EMA's scientific advice procedure. Developers can present their planned clinical programme to the HTACG and receive structured feedback on:
- Whether the proposed comparators will be considered clinically relevant
- Whether the planned clinical outcomes align with what HTA bodies consider meaningful to patients
- Whether the study design and population will generate the evidence needed for JCA purposes
The strategic value of a JSC is significant. Developers who design clinical trials without HTA input — optimising solely for EMA marketing authorisation — risk arriving at the JCA stage with an evidence package that does not satisfy HTA requirements, facing an unfavourable assessment that undermines access across the entire EU market simultaneously.
Pillar 3: Identification of Emerging Health Technologies
The third pillar creates a horizon scanning function — an EU-wide mechanism to identify medicines and health technologies that are likely to have a significant impact on public health or health systems, enabling early preparation for their assessment and access.
This function is particularly relevant for developers of genuinely novel therapies, where existing frameworks may not adequately capture the clinical value of a product — and where early dialogue with the EU HTA ecosystem can shape a more appropriate assessment pathway.
The PICO Framework: The Engine of Every JCA
At the heart of every Joint Clinical Assessment is the PICO framework — the structured methodology used to define the scope of the assessment.
PICO stands for:
- P — Population (which patients are being assessed?)
- I — Intervention (the medicine being evaluated)
- C — Comparator (what it is being compared against — the current standard of care)
- O — Outcomes (which clinical endpoints are considered relevant and meaningful?)
Understanding PICO is not optional for anyone working in EU regulatory affairs or market access — it is the foundational framework around which all JCA strategy is built.
Why PICO Is More Complex Than It Appears
One of the most significant operational challenges of the EU HTA Regulation is the proliferation of PICOs across different member states. Unlike the FDA, which defines comparators based on regulatory requirements, European HTA bodies base comparator choices on actual clinical practice in their respective healthcare systems.
The same medicine — approved for the same indication — may face entirely different comparators in Germany, France, Spain, and Poland, reflecting different national standards of care. A single product can therefore generate multiple PICOs for a single JCA, each requiring separate evidence evaluation. A research simulation in metastatic non-small cell lung cancer (mNSCLC) identified an astonishing 67 distinct PICOs for a single treatment across 25 EU countries.
Oncology already dominates the early JCA landscape: research covering 35 PICO scoping exercises found that 74% of health technology evaluations involve oncology products — reflecting both the volume of new oncology authorisations and the complexity of PICO scoping in a rapidly evolving treatment landscape.
The consolidation of PICOs — deciding which PICOs across 27 member states can be grouped together for a single evidence evaluation — is one of the most technically challenging and methodologically contentious aspects of the JCA process. Clearer guidance from the HTACG on consolidation criteria is widely regarded as one of the most urgent needs of the emerging system.
Lessons from the First Year: What the JCA System Has Taught Industry
The JCA system completed its first full year of operation in January 2026, and the lessons emerging from that year are already reshaping how the pharmaceutical industry approaches European market access strategy.
Lower-Than-Expected JCA Volume in Year One
The initial year of operation saw fewer JCAs than anticipated. The combination of tight submission deadlines, the complexity of PICO scoping, and the operational challenges of establishing a genuinely new pan-European process meant that throughput was lower than the regulation's architects had projected.
This is being addressed as we move into 2026, with a forecasted increase in JCA volume focused on oncology, advanced therapies, and high-risk medical devices. The operational infrastructure is maturing rapidly, and the lessons of the first wave are being incorporated into process refinements.
The First Completed JCA: What Tovorafenib Teaches the Industry
The completion of the first-ever JCA report on tovorafenib (Ojemda®) on 30 April 2026 was significant beyond its symbolic milestone status. For market access strategists, the tovorafenib JCA is a case study in how the PICO scoping process unfolds in practice — from the consolidation of national PICOs through to the evidence assessment methodology applied by the HTACG.
The report was completed well within the 30-day post-marketing-authorisation timeline — a positive signal for the operational capacity of the system. But the more important signal is methodological: the tovorafenib JCA is now being studied intensively by pharmaceutical companies preparing future JCA submissions, for the insights it provides into how the HTACG handles evidence gaps, comparator selection, and outcome relevance in a rare paediatric oncology setting.
The German IQWiG Influence: High Evidentiary Standards
A frequently noted challenge in the emerging JCA system is the significant influence of Germany's IQWiG (Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen) — one of the most rigorous and demanding HTA bodies in Europe — on the evidence standards applied within the JCA process. IQWiG acted as assessor or co-assessor in four of the first wave of oncology JCAs.
Critics and developers have raised concerns that evidence requirements calibrated to the IQWiG standard may be unrealistic for rare disease developers, where small patient populations make large randomised controlled trials structurally impossible. Designing adequate clinical evidence for a disease affecting 1 in 100,000 patients under the same evidentiary framework as a common oncology indication is not merely difficult — it may be scientifically unfeasible.
This tension between methodological rigour and rare disease reality is one of the most important unresolved questions of the EU HTA system, and one that the HTACG will need to address as the scope expands to include orphan medicines in 2028.
How the EU HTA Regulation Changes Clinical Trial Design
The most profound long-term impact of the EU HTA Regulation is not on market access teams — it is on how clinical development programmes are designed from the very beginning.
The old model — design the trial for EMA approval, then adapt the evidence for national HTA submissions — is no longer viable. The JCA process begins at marketing authorisation submission. There is no time to retrospectively adapt evidence. The trial design IS the HTA strategy.
The Dual-Purpose Trial Design Imperative
Leading pharmaceutical companies are now building dual-purpose trial designs that satisfy both EMA regulatory requirements and EU HTA JCA requirements simultaneously. This requires:
- Early PICO modelling — identifying the likely PICOs across key EU markets before the trial begins, and designing to generate evidence relevant to all of them
- Comparator alignment — selecting active comparators that are clinically relevant to HTA bodies, not just placebo or standard of care defined by regulatory convention
- Outcome selection — including patient-relevant outcomes (quality of life, functional outcomes, patient-reported endpoints) alongside traditional efficacy endpoints, since HTA bodies weight these differently from regulators
- Subgroup planning — anticipating how HTA bodies will subdivide the patient population and ensuring adequate statistical power for subgroup analyses
Oncology: The Hardest Case
Oncology presents the most acute challenge for dual-purpose trial design. Treatment sequencing in oncology evolves rapidly — a standard of care comparator relevant at the start of a trial may already be outdated by the time the trial completes. In a disease area where treatment options are changing every 12–18 months, locking in a comparator three to five years before submission is an inherently difficult strategic call.
Rare Diseases: A Different Kind of Challenge
For rare disease developers, the challenge is structural rather than strategic. Small patient populations cannot support the large, randomised, comparative trials that HTA bodies — particularly those influenced by IQWiG methodology — prefer. Natural history studies, real-world evidence, and novel statistical approaches are increasingly essential components of evidence packages for rare disease JCAs. Their role within the JCA evidence framework is still being defined.
Advanced Therapies: The Long-Term Data Problem
ATMPs — gene therapies, cell therapies, and tissue-engineered products — present a particular challenge because their clinical benefit often manifests over decades, while JCA evidence requirements must be met at the time of marketing authorisation. Long-term follow-up data that will ultimately validate the therapy's clinical value may simply not exist when the JCA is conducted. How the HTACG addresses this structural challenge will fundamentally shape the commercial viability of the ATMP sector in Europe.
What the EU HTA Regulation Means for Business: Strategic Priorities for 2026
For pharmaceutical companies and developers navigating the EU HTA landscape, here are the actions that separate prepared organisations from reactive ones.
✅ Initiate Joint Scientific Consultations early — earlier than feels necessary
The JSC process is the most powerful tool available for aligning clinical development with JCA requirements before it is too late to act on the feedback. Companies that engage with this process at Phase II — not Phase III — gain the most actionable intelligence.
✅ Build HTA expertise into clinical development teams from day one
Market access strategy can no longer be a Phase III activity. Clinical operations, medical affairs, and regulatory affairs teams need to understand HTA requirements and PICO frameworks from the point of programme initiation.
✅ Conduct PICO modelling across key EU markets before trial design is finalised
Identifying the likely PICOs — and the evidence they will require — before a trial starts is the single most valuable exercise a development team can conduct. Discovering that your trial's comparator is clinically irrelevant to five major EU markets after the trial is complete is not a regulatory problem. It is a business failure.
✅ Invest in real-world evidence strategies as a JCA complement
RWE is increasingly valued as a supplementary evidence source in JCA dossiers, particularly for rare diseases, ATMPs, and products where RCT evidence has structural limitations. An RWE strategy should be built in parallel with the clinical trial programme.
✅ Monitor the JCA output from 2026 closely
The early JCA reports — starting with tovorafenib — will provide the industry's most detailed insight into how the HTACG applies its methodology in practice. These reports should be studied carefully by market access and regulatory affairs teams preparing future JCA submissions.
The Career Opportunity: Why EU HTA Expertise Is One of the Most Valuable Skills in Regulatory Affairs and Market Access
The EU HTA Regulation has created a new category of professional demand across the life sciences industry — one that sits at the intersection of regulatory affairs, market access, health economics, and clinical strategy.
The Demand Is Real and Growing
- The Regulatory Affairs Specialist and Health Economics and Outcomes Research (HEOR) Specialist are among the fastest-growing roles in European life sciences in 2026
- The HTA Commission Conference held in July 2025 explicitly highlighted the urgent need for trained assessors — both within national HTA bodies and within industry — as one of the most pressing capacity challenges facing the system
- Professionals who can navigate the dual demands of EMA regulatory submissions and EU HTA JCA requirements are genuinely scarce — and the market reflects that
- EU regulatory affairs entry-level roles command €35,000–€50,000, with mid-level roles at €50,000–€70,000 and senior market access specialists regularly exceeding €80,000–€100,000+
- The international regulatory community is closely watching the EU's JCA approach as nations globally develop their own HTA frameworks — making EU HTA expertise increasingly relevant beyond Europe
The skills now in demand go beyond traditional regulatory affairs competency. The EU HTA Regulation has elevated the need for professionals who can:
- Understand and apply the PICO framework across multiple national clinical contexts
- Navigate the relationship between EMA scientific advice and HTA Joint Scientific Consultations
- Build evidence generation plans that serve regulatory and HTA requirements simultaneously
- Interpret and apply evolving HTACG guidance to product-specific development strategies
- Communicate clinical evidence value to diverse stakeholders — regulators, HTA bodies, payers, and clinicians
Choosing the Right Training: Building the Skills That the Market Needs
The EU HTA Regulation has significantly raised the bar on what pharmaceutical and biotech employers expect from regulatory affairs and market access professionals.
The consistent message from EU regulatory and market access employers in 2026 is the same as elsewhere in the industry: they want candidates who have engaged with real regulatory documents and processes — not just candidates who have completed online assessments. As the EU HTA system matures and the JCA process becomes the lived reality of pharmaceutical market access, professionals who combine genuine regulatory knowledge with practical document experience will be the most competitive in an increasingly specialised hiring market.
Key Takeaways
The EU HTA Regulation is not a future consideration — it is an operational reality shaping how clinical evidence is generated, evaluated, and used to support patient access to medicines right now. Whether you are a pharmaceutical company, a developer of advanced therapies, or a regulatory professional building your career, the direction of travel is clear:
- ✅ Clinical trial design must now serve both EMA and HTA requirements — dual-purpose design is the new baseline for EU-facing development programmes
- ✅ The PICO framework is central — understanding it, modelling it early, and designing evidence to satisfy it across multiple member states is the most important market access skill in Europe
- ✅ Joint Scientific Consultations are an underused strategic tool — developers who engage early gain an enormous advantage over those who do not
- ✅ JCA output is now a learning resource — the tovorafenib report and those that follow should be studied intensively by market access and regulatory teams
- ✅ The scope is expanding — orphan medicines in 2028, all products by 2030. Companies that build HTA-aware development programmes now are building the capabilities they will need at scale
Ready to Build Your Career at the Forefront of EU Regulatory Affairs and Market Access?
The EU HTA Regulation has permanently changed the skills profile demanded of regulatory affairs and market access professionals. The intersection of clinical evidence strategy, EMA regulatory expertise, and EU HTA knowledge is where the most impactful — and most rewarding — careers in pharmaceutical regulation are being built right now.
At Entry to Regulatory, we provide training courses for anyone trying to build a career in Regulatory Affairs — no previous experience required. Our programme covers the EU regulatory frameworks that underpin the HTA system, gives you hands-on experience with real regulatory documents, and provides the career support that turns course completion into employment.
Here is what you get when you train with us:
- 📋 50+ CPD hours covering EU, US, and UK regulatory frameworks — the foundation every employer in the EU regulatory and market access space expects
- 🔬 Real-life work assignments on actual regulatory documents — demonstrable, CV-ready experience that makes you competitive from day one
- 🧑💼 Dedicated job support — CV reviews, mock interviews, and career mentoring from people who know the regulatory affairs hiring market
- 🌐 A professional community of peers, graduates, and industry connections that support your career long after the course ends
- 🏆 Proven graduate outcomes — UK roles paying upwards of £50,000 and US roles offering $100,000+, with graduates landing positions within weeks to months
Whether you are entering the industry for the first time or looking to build on an existing science or healthcare background, we can help you develop the skills, experience, and confidence to compete — and succeed — in one of the most dynamic regulatory landscapes in the world.
About the Author: Rabiea is an Honorary Associate Professor at UCL, former MHRA Health Authority reviewer, and CEO of Entry to Regulatory and Advanced Regulatory Consulting. After transitioning from retail pharmacy to regulatory affairs, she has dedicated her career to helping others make the same successful career change. Connect with her on LinkedIn for the latest regulatory affairs insights and career advice.
Comments